Anti-CD19 CAR T-cell therapy (Fujian Medical University)

抗CD19嵌合抗原T细胞疗法

Report date: 2024/11/20 20:00:31

Base Information

Drug NameAnti-CD19 CAR T-cell therapy (Fujian Medical University)

Drug Alias Nameanti-CD19-scFv-4-1BB-CD3zeta CAR-T-cells

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 3 Clinical)

Highest Status in ChinaPending

Originator CompaniesFujian Medical University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesFujian Medical University

Active IndicationsN/A

Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A